Skip to main content

CCTG Connection



Published:
Category: Trials

The CCTG PA.7 trial: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma met its target accrual of 180 patients on 26-JUL-2018 and is now officially closed to accrual.

Read More

Published:
Category: Trials
Please be aware that two trials have recently been permenantly closed:
  1. MAC8 (NSABP B-37): A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer.
  2. HEC1 (CALGB 80802): Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
If you have any questions please contact Christine Bertrim, Trial Manag
Read More



Published:
Category: Group updates

The DTL has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials.  The first National Clinical Trials Network Trial (NCTN) where CCTG is using the DTL is the BLC.4 trial.  An active DTL is now a requirement for CCTG sites following approval of the BLC.4 Revision #3.  Other upcoming studies that will be using the DTL initially include MAC.24 and REC.4.  

Read More

Published:
Category: Group updates

The Canadian Cancer Trials Group (CCTG) Operations and Statistical Centre (OSC), based at the Queen’s University Cancer Research Institute in Kingston, Ontario is seeking a physician with hematology or oncology training with demonstrated interest and experience with developing and cancer therapy trials.

Senior investigators work at the OSC with members of the investigational new drug and disease-specific and trial endpoint committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda.

Read More

Published:
Category: News

The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research.

Read More



Published:
Category: Publications
Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
 
V
Read More

Published:
Category: Trials

The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC).  Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.

Read More



Published:
Category: Group updates
Implementation of the Delegation of Tasks Log (DTL) in RIPPLE

The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.

Read More